Selected research
Market Structure
Global Immuno-Oncology Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Immuno-Oncology Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Immuno-Oncology Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Immuno-Oncology Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Immuno-Oncology Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Immuno-Oncology Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Immuno-Oncology Service include Crown Bioscience, Bio-Techne, Abcam, WuXi AppTec, Shanghai ChemPartner, George Clinical, Laboratory Corporation of America® Holdings, Medpace and Genscript, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Immuno-Oncology Service market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Immuno-Oncology Service and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Immuno-Oncology Service revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Immuno-Oncology Service market size, projected growth trends, production technologies, key applications, and end-use industries.
Immuno-Oncology Service Segment by Company
Crown Bioscience
Bio-Techne
Abcam
WuXi AppTec
Shanghai ChemPartner
George Clinical
Laboratory Corporation of America® Holdings
Medpace
Genscript
Shanghai Novamab Biopharmaceuticals
LIDE
TransCure bioServices
Immuno-Oncology Service Segment by Type
Basic Research
Clinical Research
Immuno-Oncology Service Segment by Application
Pharmaceutical Companies
Medical Device Companies
Other
Immuno-Oncology Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immuno-Oncology Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Immuno-Oncology Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immuno-Oncology Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Immuno-Oncology Service in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Immuno-Oncology Service industry.
Chapter 3: Detailed analysis of Immuno-Oncology Service companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Immuno-Oncology Servicerevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Basic Research
- Clinical Research
Applications
- Pharmaceutical Companies
- Medical Device Companies
- Other
Companies covered
- Crown Bioscience
- Bio-Techne
- Abcam
- WuXi AppTec
- Shanghai ChemPartner
- George Clinical
- Laboratory Corporation of America® Holdings
- Medpace
- Genscript
- Shanghai Novamab Biopharmaceuticals
- LIDE
- TransCure bioServices
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Immuno-Oncology Service Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Basic Research
- 1.2.3 Clinical Research
- 1.3 Market Analysis by Application
- 1.3.1 Global Immuno-Oncology Service Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Pharmaceutical Companies
- 1.3.3 Medical Device Companies
- 1.3.4 Other
- 1.4 Global Market Growth Prospects
- 1.5 Global Immuno-Oncology Service Growth Trends by Region
- 1.5.1 Global Immuno-Oncology Service Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Immuno-Oncology Service Market Size by Region (2021-2026)
- 1.5.3 Immuno-Oncology Service Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Immuno-Oncology Service Market Dynamics
- 2.1 Immuno-Oncology Service Industry Trends
- 2.2 Immuno-Oncology Service Industry Drivers
- 2.3 Immuno-Oncology Service Industry Opportunities and Challenges
- 2.4 Immuno-Oncology Service Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Immuno-Oncology Service Revenue by Company (2021-2026)
- 3.2 Global Immuno-Oncology Service Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Immuno-Oncology Service Key Company Head office and Area Served
- 3.4 Global Immuno-Oncology Service Company, Product Type & Application
- 3.5 Global Immuno-Oncology Service Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Immuno-Oncology Service Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Immuno-Oncology Service Players Market Share by Revenue in 2025
- 3.6.3 2025 Immuno-Oncology Service Tier 1, Tier 2, and Tier 3
4 Immuno-Oncology Service Market by Type
- 4.1 Global Immuno-Oncology Service Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Immuno-Oncology Service Market Size by Type (2021-2032)
- 4.3 Global Immuno-Oncology Service Market Size Share by Type (2021-2032)
5 Immuno-Oncology Service Market by Application
- 5.1 Global Immuno-Oncology Service Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Immuno-Oncology Service Market Size by Application (2021-2032)
- 5.3 Global Immuno-Oncology Service Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Crown Bioscience
- 6.1.1 Crown Bioscience Company Information
- 6.1.2 Crown Bioscience Business Overview
- 6.1.3 Crown Bioscience Immuno-Oncology Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Crown Bioscience Immuno-Oncology Service Product Portfolio
- 6.1.5 Crown Bioscience Recent Developments
- 6.2 Bio-Techne
- 6.2.1 Bio-Techne Company Information
- 6.2.2 Bio-Techne Business Overview
- 6.2.3 Bio-Techne Immuno-Oncology Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Bio-Techne Immuno-Oncology Service Product Portfolio
- 6.2.5 Bio-Techne Recent Developments
- 6.3 Abcam
- 6.3.1 Abcam Company Information
- 6.3.2 Abcam Business Overview
- 6.3.3 Abcam Immuno-Oncology Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Abcam Immuno-Oncology Service Product Portfolio
- 6.3.5 Abcam Recent Developments
- 6.4 WuXi AppTec
- 6.4.1 WuXi AppTec Company Information
- 6.4.2 WuXi AppTec Business Overview
- 6.4.3 WuXi AppTec Immuno-Oncology Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 WuXi AppTec Immuno-Oncology Service Product Portfolio
- 6.4.5 WuXi AppTec Recent Developments
- 6.5 Shanghai ChemPartner
- 6.5.1 Shanghai ChemPartner Company Information
- 6.5.2 Shanghai ChemPartner Business Overview
- 6.5.3 Shanghai ChemPartner Immuno-Oncology Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Shanghai ChemPartner Immuno-Oncology Service Product Portfolio
- 6.5.5 Shanghai ChemPartner Recent Developments
- 6.6 George Clinical
- 6.6.1 George Clinical Company Information
- 6.6.2 George Clinical Business Overview
- 6.6.3 George Clinical Immuno-Oncology Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 George Clinical Immuno-Oncology Service Product Portfolio
- 6.6.5 George Clinical Recent Developments
- 6.7 Laboratory Corporation of America® Holdings
- 6.7.1 Laboratory Corporation of America® Holdings Company Information
- 6.7.2 Laboratory Corporation of America® Holdings Business Overview
- 6.7.3 Laboratory Corporation of America® Holdings Immuno-Oncology Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Laboratory Corporation of America® Holdings Immuno-Oncology Service Product Portfolio
- 6.7.5 Laboratory Corporation of America® Holdings Recent Developments
- 6.8 Medpace
- 6.8.1 Medpace Company Information
- 6.8.2 Medpace Business Overview
- 6.8.3 Medpace Immuno-Oncology Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Medpace Immuno-Oncology Service Product Portfolio
- 6.8.5 Medpace Recent Developments
- 6.9 Genscript
- 6.9.1 Genscript Company Information
- 6.9.2 Genscript Business Overview
- 6.9.3 Genscript Immuno-Oncology Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Genscript Immuno-Oncology Service Product Portfolio
- 6.9.5 Genscript Recent Developments
- 6.10 Shanghai Novamab Biopharmaceuticals
- 6.10.1 Shanghai Novamab Biopharmaceuticals Company Information
- 6.10.2 Shanghai Novamab Biopharmaceuticals Business Overview
- 6.10.3 Shanghai Novamab Biopharmaceuticals Immuno-Oncology Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Shanghai Novamab Biopharmaceuticals Immuno-Oncology Service Product Portfolio
- 6.10.5 Shanghai Novamab Biopharmaceuticals Recent Developments
- 6.11 LIDE
- 6.11.1 LIDE Company Information
- 6.11.2 LIDE Business Overview
- 6.11.3 LIDE Immuno-Oncology Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 LIDE Immuno-Oncology Service Product Portfolio
- 6.11.5 LIDE Recent Developments
- 6.12 TransCure bioServices
- 6.12.1 TransCure bioServices Company Information
- 6.12.2 TransCure bioServices Business Overview
- 6.12.3 TransCure bioServices Immuno-Oncology Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 TransCure bioServices Immuno-Oncology Service Product Portfolio
- 6.12.5 TransCure bioServices Recent Developments
7 North America
- 7.1 North America Immuno-Oncology Service Market Size (2021-2032)
- 7.2 North America Immuno-Oncology Service Market Size by Type
- 7.2.1 North America Immuno-Oncology Service Market Size by Type (2021-2026)
- 7.2.2 North America Immuno-Oncology Service Market Size by Type (2027-2032)
- 7.2.3 North America Immuno-Oncology Service Market Share by Type (2021-2032)
- 7.3 North America Immuno-Oncology Service Market Size by Application
- 7.3.1 North America Immuno-Oncology Service Market Size by Application (2021-2026)
- 7.3.2 North America Immuno-Oncology Service Market Size by Application (2027-2032)
- 7.3.3 North America Immuno-Oncology Service Market Share by Application (2021-2032)
- 7.4 North America Immuno-Oncology Service Market Size by Country
- 7.4.1 North America Immuno-Oncology Service Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Immuno-Oncology Service Market Size by Country (2021-2026)
- 7.4.3 North America Immuno-Oncology Service Market Size by Country (2027-2032)
- 7.4.4 North America Immuno-Oncology Service Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Immuno-Oncology Service Market Size (2021-2032)
- 8.2 Europe Immuno-Oncology Service Market Size by Type
- 8.2.1 Europe Immuno-Oncology Service Market Size by Type (2021-2026)
- 8.2.2 Europe Immuno-Oncology Service Market Size by Type (2027-2032)
- 8.2.3 Europe Immuno-Oncology Service Market Share by Type (2021-2032)
- 8.3 Europe Immuno-Oncology Service Market Size by Application
- 8.3.1 Europe Immuno-Oncology Service Market Size by Application (2021-2026)
- 8.3.2 Europe Immuno-Oncology Service Market Size by Application (2027-2032)
- 8.3.3 Europe Immuno-Oncology Service Market Share by Application (2021-2032)
- 8.4 Europe Immuno-Oncology Service Market Size by Country
- 8.4.1 Europe Immuno-Oncology Service Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Immuno-Oncology Service Market Size by Country (2021-2026)
- 8.4.3 Europe Immuno-Oncology Service Market Size by Country (2027-2032)
- 8.4.4 Europe Immuno-Oncology Service Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Immuno-Oncology Service Market Size (2021-2032)
- 9.2 China Immuno-Oncology Service Market Size by Type
- 9.2.1 China Immuno-Oncology Service Market Size by Type (2021-2026)
- 9.2.2 China Immuno-Oncology Service Market Size by Type (2027-2032)
- 9.2.3 China Immuno-Oncology Service Market Share by Type (2021-2032)
- 9.3 China Immuno-Oncology Service Market Size by Application
- 9.3.1 China Immuno-Oncology Service Market Size by Application (2021-2026)
- 9.3.2 China Immuno-Oncology Service Market Size by Application (2027-2032)
- 9.3.3 China Immuno-Oncology Service Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Immuno-Oncology Service Market Size (2021-2032)
- 10.2 Asia Immuno-Oncology Service Market Size by Type
- 10.2.1 Asia Immuno-Oncology Service Market Size by Type (2021-2026)
- 10.2.2 Asia Immuno-Oncology Service Market Size by Type (2027-2032)
- 10.2.3 Asia Immuno-Oncology Service Market Share by Type (2021-2032)
- 10.3 Asia Immuno-Oncology Service Market Size by Application
- 10.3.1 Asia Immuno-Oncology Service Market Size by Application (2021-2026)
- 10.3.2 Asia Immuno-Oncology Service Market Size by Application (2027-2032)
- 10.3.3 Asia Immuno-Oncology Service Market Share by Application (2021-2032)
- 10.4 Asia Immuno-Oncology Service Market Size by Country
- 10.4.1 Asia Immuno-Oncology Service Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Immuno-Oncology Service Market Size by Country (2021-2026)
- 10.4.3 Asia Immuno-Oncology Service Market Size by Country (2027-2032)
- 10.4.4 Asia Immuno-Oncology Service Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Immuno-Oncology Service Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Immuno-Oncology Service Market Size by Type
- 11.2.1 South America, Middle East & Africa Immuno-Oncology Service Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Immuno-Oncology Service Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Immuno-Oncology Service Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Immuno-Oncology Service Market Size by Application
- 11.3.1 South America, Middle East & Africa Immuno-Oncology Service Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Immuno-Oncology Service Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Immuno-Oncology Service Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Immuno-Oncology Service Market Size by Country
- 11.4.1 South America, Middle East & Africa Immuno-Oncology Service Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Immuno-Oncology Service Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Immuno-Oncology Service Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Immuno-Oncology Service Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst